CRNX - Crinetics Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CRNX is currently covered by 10 analysts with an average price target of $55.5. This is a potential upside of $27.62 (99.07%) from yesterday's end of day stock price of $27.88.

Crinetics Pharmaceuticals's activity chart (see below) currently has 33 price targets and 76 ratings on display. The stock rating distribution of CRNX is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 65.45% with an average time for these price targets to be met of 438.17 days.

Highest price target for CRNX is $91, Lowest price target is $81, average price target is $72.2.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 27-Jun-2025. First documented stock forecast 13-Aug-2018.

Currently out of the existing stock ratings of CRNX, 53 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$81

$53.12 (190.53%)

$81

1 months 13 days ago
(27-Jun-2025)

14/18 (77.78%)

$51.04 (170.36%)

265

Buy

$91

$63.12 (226.40%)

$87

5 months 12 days ago
(28-Feb-2025)

9/16 (56.25%)

$55.22 (154.33%)

394

Buy

$90

$62.12 (222.81%)

$65

10 months 24 days ago
(16-Sep-2024)

3/6 (50%)

$36.06 (66.85%)

131

Buy

$73

$45.12 (161.84%)

$74

1 years ago
(09-Aug-2024)

5/7 (71.43%)

$25.36 (53.23%)

146

Buy

$54

$26.12 (93.69%)

$47

1 years 1 months ago
(09-Jul-2024)

9/9 (100%)

$5.77 (11.96%)

183

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CRNX (Crinetics Pharmaceuticals) average time for price targets to be met?

On average it took 438.17 days on average for the stock forecasts to be realized with a an average price target met ratio 65.45

Which analyst has the current highest performing score on CRNX (Crinetics Pharmaceuticals) with a proven track record?

CHARLES DUNCAN

Which analyst has the most public recommendations on CRNX (Crinetics Pharmaceuticals)?

Charles Duncan works at CANTOR FITZGERALD and has 12 price targets and 8 ratings on CRNX

Which analyst is the currently most bullish on CRNX (Crinetics Pharmaceuticals)?

Yasmeen Rahimi with highest potential upside - $69.12

Which analyst is the currently most reserved on CRNX (Crinetics Pharmaceuticals)?

Tyler Van Buren with lowest potential downside - -$0

Crinetics Pharmaceuticals in the News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail...

Crinetics (CRNX) Q2 Revenue Jumps 150%

Key Points GAAP revenue of $1.0 million in Q2 2025 exceeded analyst expectations by 62.9%, driven by licensing income. GAAP net loss per share widened to $(1.23) in Q2 2025, reflecting increased R&D and commercial launch investment. Cash reserves remained strong at $1.2 billion as of Q2 2025 and are projected to support operations into...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?